Induction Chemotherapy of Docetaxel and Cisplatin for the Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Although concurrent chemoradiotherapy (CCRT) has been considered as a standard treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN), this treament is associated with increased toxicities such as mucositis and dermatitis. As a result, the dose intensity can be reduced and interruptions of radiotherapy are more common for CCRT than for sequential treatment, especially for the elderly patients. This prospective study was performed to assess the efficacy and safety profiles of the induction chemotherapy of docetaxel and cisplatin for elderly patients with locally advanced SCCHN. Materials and Methods: Patients over 65 years of age with locally advanced SCCHN were treated with docetaxel (70 mg/m2) and cisplatin (75 mg/m2) every 21 days. The chemotherapy consisted of two cycles with a third cycle that was administered to the responding patients. Patients who did not respond to initial chemotherapy underwent radiotherapy as a definitive local treatment. Results: Fifty patients were enrolled in this study and 44 patients were assessable for response and toxicity. The overall response rate was 88%, 16 patients (36%) achieved a complete response and 23 patients (52%) achieved a partial response. After a median follow-up of 24 months (range: 9～38 months) the median disease free period and overall survival period had not yet been reached. The one year and two year survival rates were 89% and 70%, respectively. The most common grade 3/4 adverse event was neutropenia, which occurred in 33 patients (75%) and 4 patients had febrile neutropenia. Conclusion: Combination chemotherapy of docetaxel and cisplatin is an effective regimen with an acceptable safety profile as the induction treatment for elderly patients suffering with SCCHN. (Cancer Res Treat. 2007; 39:1-5)
Abstract
PURPOSE: Although concurrent chemoradiotherapy (CCRT) has been considered as a standard treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN), this treament is associated with increased toxicities such as mucositis and dermatitis. As a result, the dose intensity can be reduced and interruptions of radiotherapy are more common for CCRT than for sequential treatment, especially for the elderly patients. This prospective study was performed to assess the efficacy and safety profiles of the induction chemotherapy of docetaxel and cisplatin for elderly patients with locally advanced SCCHN. 0aMATERIALS AND METHODS: Patients over 65 years of age with locally advanced SCCHN were treated with docetaxel (70 mg/m(2)) and cisplatin (75 mg/m(2)) every 21 days. The chemotherapy consisted of two cycles with a third cycle that was administered to the responding patients. Patients who did not respond to initial chemotherapy underwent radiotherapy as a definitive local treatment.0aRESULTS: Fifty patients were enrolled in this study and 44 patients were assessable for response and toxicity. The overall response rate was 88%, 16 patients (36%) achieved a complete response and 23 patients (52%) achieved a partial response. After a median follow-up of 24 months (range: 9~38 months) the median disease free period and overall survival period had not yet been reached. The one year and two year survival rates were 89% and 70%, respectively. The most common grade 3/4 adverse event was neutropenia, which occurred in 33 patients (75%) and 4 patients had febrile neutropenia. 0aCONCLUSION: Combination chemotherapy of docetaxel and cisplatin is an effective regimen with an acceptable safety profile as the induction treatment for elderly patients suffering with SCCHN.
참고문헌 (19)
- Parkin DM, "Estimates of the worldwide incidence of 25 major cancers in 1990", 80, pp.827~41 (1999)
- Zbaren P, "Frequency and sites of distant metastases in head and neck squamous cell carcinoma", 113, pp.762~4 (1987)
- Vokes EE, "Chemotherapy added to locoregional treatment for head and neck squamous- cell carcinoma Three meta-analyses of updated individual data Meta-analysis of chemotherapy on head and neck cancer The expanding role of systemic therapy in head and neck cancer", pig(n jp), pp.949 1743~55 52
- Vokes EE, "Weekly carboplatin and paclitaxel followed by concomitant paclitaxel curative and organ-preserving therapy for advanced head and neck cancer", pp.320~6 (2003)
- Lefebvre JL, "Larynx preservation in pyriform sinus cancer:preliminary results of a European organization for research and treatment of cancer phase III trial-EORTC head and neck cancer cooperative group", 88, pp.890~9 (1996)
- Licitra L, "Primary chemotherapy in resectable oral cavity squamous cell cancer:a randomized controlled trial", 21, pp.327~33 (2003)
- Hill C, "Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma", pp.1594~8 (2000)
- Planting AS, "an active regimen in patients with locally advanced recurrent or metastatic squamous cell carcinoma of the head and neck Results of a phase II study of the EORTC early clinical studies group", pp.119~22 (1999)
- Glisson BS, "Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck", 20, pp.1593~99 (2002)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors", 92, pp.205~16 (2000)
- Ozols RF, "Mechanisms of cross- resistance between radiation and antineoplastic drugs", 6, pp.159~65 (1988)
- Ensley JF, "Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck", 54, pp.811~4 (1984)
- Browman GP, "Evidence-based recommendations against neoadjuvant chemotherapy for routine management of patients with squamous cell head and neck cancer", 12, pp.662~70 (1994)
- Rademaker AW, "Patterns of failure prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy", pp.1179~86 (2004)
- Dreyfuss AI, "Docetaxel:an active drug for squamous cell carcinoma of the head and neck", 14, pp.1672~8 (1996)
- Hanauske A, "an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck", pp.533~7 (1994)
- Busse PM, "Induction chemotherapy with docetaxel and leucovorin for squamous cell carcinoma of the head and neck", pp.1331~9 (1998)
- Van Herpen C, "as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck a phase III trial of the EORTC head and neck cancer group", pp.~5508 (2004)
- de Mulder PH, "Randomized comparison of cisplatin in recurrent or metastatic squamous cell carcinoma of the head and neck A phase III study of the EORTC head and neck cancer cooperative group", pp.521~6 (1994), bleomycin and vincristine